Gendius

Gendius is a company that aims to bring pharmaceuticals and health economics, through clinical research and evidence, to the mobile health market. Their latest innovation, Intellin, is an intelligent remote management diabetes platform, with over 140,000 downloads so far. The COVID-19 crisis has highlighted the need for remote home monitoring of patients, and the company feels that its product is a suitable contender in this domain. Intellin has a reliable connection to over 150 medical devices and apps, and also consists of a two-way communication setup with a healthcare professional via a secure dashboard. Gendius is registered as an approved vendor with AstraZeneca in Saudi Arabia and looks to establish deeper relations with the National Health Service (UK) to create a demand for its product. The company will use the investment to scale its business globally, drive commercialisation, offer an opportunity to its stakeholders, and target venture capital.

Gendius Rating Review

Pitch rating powered by CROWDRATING™

Rated on 30/06/2020

Pitch Rated

84%

Gold

Management

90%

Product

86%

Investment

75%

£19,956,676
pre-money valuation

0.25%
equity available

902
investors

£429
pledge per investor

08525197
company number

Administration
company status

13/05/2013
incorporated 11 years

£0.79
share price

Previous Funding rounds

25 Apr 24

Crowdcube

£386,829 / 774%

83.67%

Officers

Christopher Michael Kennedy SPENCER
Appointed: 21-11-2023

Christopher Michael Kennedy SPENCER
Appointed: 02-04-2018

Christopher Michael Kennedy SPENCER
Appointed: 16-05-2017

News

Gendius receives UKCA mark for CKD Screen Prioritizer - Med-Tech Innovation
04/09/2023 Med-Tech Innovation

Gendius working with Astrazeneca to improve diabetes care via its Intellin system - BioWorld Online
30/06/2020 BioWorld Online

Valuations in Health and Fitness

Carocell Bio Limited	£6.1M
PulmoBioMed	£4.0M
Optimise BP	£474.1K

What the ratings mean

49% and under
We suggest potential investors carry out further study of their own 50-64%
Room for improvement 65-79%
Worth considering 80%+
Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

See full risk warning

Click here for more information on our ratings

Management 90%

Skills 91%

Gendius has a skilled and diverse team in place covering the roles of management, platform development, and marketing and finance. The CEO is successful in creating and selling profitable businesses from start-ups. He brings skills of starting up businesses, successful market access, driving profit before tax, setting brand strategy and objectives, developing and motivating organisations as well as liaising with global business units. The Co-founder is an experienced Sales Director within the Pharmaceutical Industry having expertise in pharmaceuticals sales, product launch, and market access. The Lead Developer is a full-stack web and mobile developer with coding and technical skills. Sales and Marketing are run by a marketer along with various PR and Marketing Agencies. Her specialities include brand design and experience, events management, visual merchandising, product promotion, trend prediction, public relations, advertising, online journalism, and copywriting. The Chairman of the company is proficient in the fields of med-tech, life sciences, social impact, startups, funding, and health and wellness. Operating at a pre-profit stage and planning to raise £5 million in the near future.

Visit Pitch on Crowdcube
More about Crowdcube

0 comments

Funding progress

More from Health and Fitness

Carocell Bio Limited Envestors Health and Fitness EIS

Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.

days to go: Extended investment: Withheld

PulmoBioMed Envestors Health and Fitness EIS

PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.

days to go: Extended investment: £295,000

Optimise BP Envestors Health and Fitness EIS

Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.

days to go: TBC investment: £127,001